| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
B Inhibition1
Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114 [J. C. C.]; Department of Biology [A. S. B.], UNC Lineberger Comprehensive Cancer Center [J. C. C., R. L., M. H., K. A., A. S. B], and UNC Curriculum in Genetics and Molecular Biology [A. S. B.], University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599; and Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts 02139 [P. J. E., J. A.]
Inducible activation of nuclear factor-
B (NF-B) inhibits the apoptotic response to chemotherapy and irradiation. Activation of NF-B via phosphorylation of an inhibitor protein IB leads to degradation of IB through the ubiquitin-proteasome pathway. We hypothesized that inactivation of proteasome function will inhibit inducible NF-B activation, thereby increasing levels of apoptosis in response to chemotherapy and enhancing antitumor effects. To assess the effects of proteasome inhibition on chemotherapy response, human colorectal cancer cells were pretreated with the dipeptide boronic acid analogue PS-341 (1 µM) prior to exposure to SN-38, the active metabolite of the topoisomerase I inhibitor, CPT-11. Inducible activation of NF-B and growth response were evaluated in vitro and in vivo. Effects on p53, p21, p27 and apoptosis were determined. Pretreatment with PS-341 inhibited activation of NF-B induced by SN-38 and resulted in a significantly higher level of growth inhibition (64–75%) compared with treatment with PS-341 alone (20–30%) or SN-38 alone (24–47%; P < 0.002). Combination therapy resulted in a 94% decrease in tumor size compared with the control group and significantly improved tumoricidal response to treatment compared with all treatment groups (P = 0.02). The level of apoptosis was 80–90% in the treatment group that received combination treatment compared with treatment with single agent alone (10%). Proteasome inhibition blocks chemotherapy-induced NF-B activation, leading to a dramatic augmentation of chemosensitivity and enhanced apoptosis. Combining proteasome inhibition with chemotherapy has significant potential to overcome the high incidence of chemotherapy resistance. Clinical studies are currently in development to evaluate the role of proteasome inhibition as an important adjuvant to systemic chemotherapy.
This article has been cited by other articles:
|
|
 |
|
  B. K. Bednarski, X. Ding, K. Coombe, A. S. Baldwin, and H. J. Kim Active roles for inhibitory {kappa}B kinases {alpha} and {beta} in nuclear factor-{kappa}B-mediated chemoresistance to doxorubicin Mol. Cancer Ther., July 1, 2008; 7(7): 1827 - 1835. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Kozuch, C. M. Rocha-Lima, T. Dragovich, H. Hochster, B. H. O'Neil, O. T. Atiq, J. M. Pipas, D. P. Ryan, and H.-J. Lenz Bortezomib With or Without Irinotecan in Relapsed or Refractory Colorectal Cancer: Results From a Randomized Phase II Study J. Clin. Oncol., May 10, 2008; 26(14): 2320 - 2326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Schmid, D. Kuhnhardt, P. Kiewe, S. Lehenbauer-Dehm, W. Schippinger, R. Greil, W. Lange, J. Preiss, N. Niederle, P. Brossart, et al. A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines Ann. Onc., May 1, 2008; 19(5): 871 - 876. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Baritaki, E. Suzuki, K. Umezawa, D. A. Spandidos, J. Berenson, T. R. Daniels, M. L. Penichet, A. R. Jazirehi, M. Palladino, and B. Bonavida Inhibition of Yin Yang 1-Dependent Repressor Activity of DR5 Transcription and Expression by the Novel Proteasome Inhibitor NPI-0052 Contributes to its TRAIL-Enhanced Apoptosis in Cancer Cells J. Immunol., May 1, 2008; 180(9): 6199 - 6210. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Z. Orlowski and D. J. Kuhn Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade Clin. Cancer Res., March 15, 2008; 14(6): 1649 - 1657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Hoskins, E. Marcuello, A. Altes, S. Marsh, T. Maxwell, D. J. Van Booven, L. Pare, R. Culverhouse, H. L. McLeod, and M. Baiget Irinotecan Pharmacogenetics: Influence of Pharmacodynamic Genes Clin. Cancer Res., March 15, 2008; 14(6): 1788 - 1796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Sourbier, S. Danilin, V. Lindner, J. Steger, S. Rothhut, N. Meyer, D. Jacqmin, J.-J. Helwig, H. Lang, and T. Massfelder Targeting the Nuclear Factor-{kappa}B Rescue Pathway Has Promising Future in Human Renal Cell Carcinoma Therapy Cancer Res., December 15, 2007; 67(24): 11668 - 11676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Juliger, H. Goenaga-Infante, T. A. Lister, J. Fitzgibbon, and S. P. Joel Chemosensitization of B-Cell Lymphomas by Methylseleninic Acid Involves Nuclear Factor-{kappa}B Inhibition and the Rapid Generation of Other Selenium Species Cancer Res., November 15, 2007; 67(22): 10984 - 10992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Zou, J. Kawada, L. Pesnicak, and J. I. Cohen Bortezomib Induces Apoptosis of Epstein-Barr Virus (EBV)-Transformed B Cells and Prolongs Survival of Mice Inoculated with EBV-Transformed B Cells J. Virol., September 15, 2007; 81(18): 10029 - 10036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Furuya, T. Ozaki, T. Hanamoto, M. Hosoda, S. Hayashi, P. A. Barker, K. Takano, M. Matsumoto, and A. Nakagawara Stabilization of p73 by Nuclear I{kappa}B Kinase-{alpha} Mediates Cisplatin-induced Apoptosis J. Biol. Chem., June 22, 2007; 282(25): 18365 - 18378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kashkar, A. Deggerich, J.-M. Seeger, B. Yazdanpanah, K. Wiegmann, D. Haubert, C. Pongratz, and M. Kronke NF-{kappa}B-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs Blood, May 1, 2007; 109(9): 3982 - 3988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Mulligan, C. Mitsiades, B. Bryant, F. Zhan, W. J. Chng, S. Roels, E. Koenig, A. Fergus, Y. Huang, P. Richardson, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib Blood, April 15, 2007; 109(8): 3177 - 3188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Dreicer, D. Petrylak, D. Agus, I. Webb, and B. Roth Phase I/II Study of Bortezomib Plus Docetaxel in Patients with Advanced Androgen-Independent Prostate Cancer Clin. Cancer Res., February 15, 2007; 13(4): 1208 - 1215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-Z. Ying, H.-G. Zhang, and P. W. Sanders EGF Receptor Activity Modulates Apoptosis Induced by Inhibition of the Proteasome of Vascular Smooth Muscle Cells J. Am. Soc. Nephrol., January 1, 2007; 18(1): 131 - 142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Cusack Jr., R. Liu, L. Xia, T.-H. Chao, C. Pien, W. Niu, V. J. Palombella, S. T.C. Neuteboom, and M. A. Palladino NPI-0052 Enhances Tumoricidal Response to Conventional Cancer Therapy in a Colon Cancer Model. Clin. Cancer Res., November 15, 2006; 12(22): 6758 - 6764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Catley, E. Weisberg, T. Kiziltepe, Y.-T. Tai, T. Hideshima, P. Neri, P. Tassone, P. Atadja, D. Chauhan, N. C. Munshi, et al. Aggresome induction by proteasome inhibitor bortezomib and {alpha}-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells Blood, November 15, 2006; 108(10): 3441 - 3449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Izzo, A. M. Correa, T.-T. Wu, U. Malhotra, C. K.S. Chao, R. Luthra, J. Ensor, A. Dekovich, Z. Liao, W. N. Hittelman, et al. Pretherapy nuclear factor-{kappa}B status, chemoradiation resistance, and metastatic progression in esophageal carcinoma. Mol. Cancer Ther., November 1, 2006; 5(11): 2844 - 2850. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Kwon, K. A Kim, S. O. Kim, R. Ha, W. K. Oh, M. S. Kim, H. S. Kim, G. D. Kim, J. W. Kim, M. Jung, et al. NF-{kappa}B inhibition increases chemosensitivity to trichostatin A-induced cell death of Ki-Ras-transformed human prostate epithelial cells Carcinogenesis, November 1, 2006; 27(11): 2258 - 2268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ishii, A. Pirkmaier, J. V. Alvarez, D. A. Frank, I. Keselman, D. Logothetis, J. Mandeli, M. J. O'Connell, S. Waxman, and D. Germain Cyclin d1 overexpression and response to bortezomib treatment in a breast cancer model. J Natl Cancer Inst, September 6, 2006; 98(17): 1238 - 1247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Dolcet, D. Llobet, M. Encinas, J. Pallares, A. Cabero, J. A. Schoenenberger, J. X. Comella, and X. Matias-Guiu Proteasome Inhibitors Induce Death but Activate NF-{kappa}B on Endometrial Carcinoma Cell Lines and Primary Culture Explants J. Biol. Chem., August 4, 2006; 281(31): 22118 - 22130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Obeng, L. M. Carlson, D. M. Gutman, W. J. Harrington Jr, K. P. Lee, and L. H. Boise Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells Blood, June 15, 2006; 107(12): 4907 - 4916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Khan, J. K. Stauffer, R. Williams, J. A. Hixon, R. Salcedo, E. Lincoln, T. C. Back, D. Powell, S. Lockett, A. C. Arnold, et al. Proteasome Inhibition to Maximize the Apoptotic Potential of Cytokine Therapy for Murine Neuroblastoma Tumors J. Immunol., May 15, 2006; 176(10): 6302 - 6312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Monk, G. Phillips, R. Waite, J. Kuhn, L. J. Schaaf, G. A. Otterson, D. Guttridge, C. Rhoades, M. Shah, T. Criswell, et al. Assessment of Tumor Necrosis Factor Alpha Blockade As an Intervention to Improve Tolerability of Dose-Intensive Chemotherapy in Cancer Patients J. Clin. Oncol., April 20, 2006; 24(12): 1852 - 1859. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. T. Flaherty Chemotherapy and targeted therapy combinations in advanced melanoma. Clin. Cancer Res., April 1, 2006; 12(7): 2366s - 2370s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Chung, B. Zhou, X. Liu, L. Zhu, L. M. Boo, H.-V. Nguyen, D. K. Ann, J. Song, Y. Chen, and Y. Yen SUMOylation plays a role in gemcitabine- and bortezomib-induced cytotoxicity in human oropharyngeal carcinoma KB gemcitabine-resistant clone. Mol. Cancer Ther., March 1, 2006; 5(3): 533 - 540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Scian, K. E. R. Stagliano, M. A. E. Anderson, S. Hassan, M. Bowman, M. F. Miles, S. P. Deb, and S. Deb Tumor-Derived p53 Mutants Induce NF-{kappa}B2 Gene Expression Mol. Cell. Biol., November 15, 2005; 25(22): 10097 - 10110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. G. Demicco, K. T. Kavanagh, R. Romieu-Mourez, X. Wang, S. R. Shin, E. Landesman-Bollag, D. C. Seldin, and G. E. Sonenshein RelB/p52 NF-{kappa}B Complexes Rescue an Early Delay in Mammary Gland Development in Transgenic Mice with Targeted Superrepressor I{kappa}B-{alpha} Expression and Promote Carcinogenesis of the Mammary Gland Mol. Cell. Biol., November 15, 2005; 25(22): 10136 - 10147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Uttamsingh, C. Lu, G. Miwa, and L.-S. Gan RELATIVE CONTRIBUTIONS OF THE FIVE MAJOR HUMAN CYTOCHROMES P450, 1A2, 2C9, 2C19, 2D6, AND 3A4, TO THE HEPATIC METABOLISM OF THE PROTEASOME INHIBITOR BORTEZOMIB Drug Metab. Dispos., November 1, 2005; 33(11): 1723 - 1728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Saunders Overview of drug therapy for multiple myeloma Journal of Oncology Pharmacy Practice, September 1, 2005; 11(3): 83 - 100. [Abstract] [PDF]
|
|
|
|
|
|
C. Aghajanian, D.S. Dizon, P. Sabbatini, J.J. Raizer, J. Dupont, and D.R. Spriggs Phase I Trial of Bortezomib and Carboplatin in Recurrent Ovarian or Primary Peritoneal Cancer J. Clin. Oncol., September 1, 2005; 23(25): 5943 - 5949. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Braun, S. Umbreen, M. Groll, U. Kuckelkorn, I. Mlynarczuk, M. E. Wigand, I. Drung, P.-M. Kloetzel, and B. Schmidt Tripeptide Mimetics Inhibit the 20 S Proteasome by Covalent Bonding to the Active Threonines J. Biol. Chem., August 5, 2005; 280(31): 28394 - 28401. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Y. Kim, K. A. Kim, O. Kwon, S. O. Kim, M. S. Kim, B. S. Kim, W. K. Oh, G. D. Kim, M. Jung, and J. S. Ahn NF-{kappa}B inhibition radiosensitizes Ki-Ras-transformed cells to ionizing radiation Carcinogenesis, August 1, 2005; 26(8): 1395 - 1403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Mackay, D. Hedley, P. Major, C. Townsley, M. Mackenzie, M. Vincent, P. Degendorfer, M.-S. Tsao, T. Nicklee, D. Birle, et al. A Phase II Trial with Pharmacodynamic Endpoints of the Proteasome Inhibitor Bortezomib in Patients with Metastatic Colorectal Cancer Clin. Cancer Res., August 1, 2005; 11(15): 5526 - 5533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mani and E. P. Gelmann The Ubiquitin-Proteasome Pathway and Its Role in Cancer J. Clin. Oncol., July 20, 2005; 23(21): 4776 - 4789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Pekol, J. S. Daniels, J. Labutti, I. Parsons, D. Nix, E. Baronas, F. Hsieh, L.-S. Gan, and G. Miwa HUMAN METABOLISM OF THE PROTEASOME INHIBITOR BORTEZOMIB: IDENTIFICATION OF CIRCULATING METABOLITES Drug Metab. Dispos., June 1, 2005; 33(6): 771 - 777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Chauhan, T. Hideshima, C. Mitsiades, P. Richardson, and K. C. Anderson Proteasome inhibitor therapy in multiple myeloma Mol. Cancer Ther., April 1, 2005; 4(4): 686 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Goy, A. Younes, P. McLaughlin, B. Pro, J. E. Romaguera, F. Hagemeister, L. Fayad, N. H. Dang, F. Samaniego, M. Wang, et al. Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma J. Clin. Oncol., February 1, 2005; 23(4): 667 - 675. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. V. Rajkumar, P. G. Richardson, T. Hideshima, and K. C. Anderson Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer J. Clin. Oncol., January 20, 2005; 23(3): 630 - 639. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Z. Orlowski The Ubiquitin Proteasome Pathway from Bench to Bedside Hematology, January 1, 2005; 2005(1): 220 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. DELHALLE, R. BLASIUS, M. DICATO, and M. DIEDERICH A Beginner's Guide to NF-{kappa}B Signaling Pathways Ann. N.Y. Acad. Sci., December 1, 2004; 1030(1): 1 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Blaney, M. Bernstein, K. Neville, J. Ginsberg, B. Kitchen, T. Horton, S. L. Berg, M. Krailo, and P. C. Adamson Phase I Study of the Proteasome Inhibitor Bortezomib in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study (ADVL0015) J. Clin. Oncol., December 1, 2004; 22(23): 4804 - 4809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Catley, Y.-T. Tai, R. Shringarpure, R. Burger, M. T. Son, K. Podar, P. Tassone, D. Chauhan, T. Hideshima, L. Denis, et al. Proteasomal Degradation of Topoisomerase I Is Preceded by c-Jun NH2-Terminal Kinase Activation, Fas Up-Regulation, and Poly(ADP-Ribose) Polymerase Cleavage in SN38-Mediated Cytotoxicity against Multiple Myeloma Cancer Res., December 1, 2004; 64(23): 8746 - 8753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Wang, J. Cassidy, V. O'Brien, K. M. Ryan, and E. Collie-Duguid Mechanistic and Predictive Profiling of 5-Fluorouracil Resistance in Human Cancer Cells Cancer Res., November 15, 2004; 64(22): 8167 - 8176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mabuchi, M. Ohmichi, Y. Nishio, T. Hayasaka, A. Kimura, T. Ohta, J. Kawagoe, K. Takahashi, N. Yada-Hashimoto, H. Seino-Noda, et al. Inhibition of Inhibitor of Nuclear Factor-{kappa}B Phosphorylation Increases the Efficacy of Paclitaxel in in Vitro and in Vivo Ovarian Cancer Models Clin. Cancer Res., November 15, 2004; 10(22): 7645 - 7654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Shah, D. Young, H. L. Kindler, I. Webb, B. Kleiber, J. Wright, and M. Grever Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic Neuroendocrine Tumors Clin. Cancer Res., September 15, 2004; 10(18): 6111 - 6118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. N. Papandreou and C. J. Logothetis Bortezomib as a Potential Treatment for Prostate Cancer Cancer Res., August 1, 2004; 64(15): 5036 - 5043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Fujioka, C. Schmidt, G. M. Sclabas, Z. Li, H. Pelicano, B. Peng, A. Yao, J. Niu, W. Zhang, D. B. Evans, et al. Stabilization of p53 Is a Novel Mechanism for Proapoptotic Function of NF-{kappa}B J. Biol. Chem., June 25, 2004; 279(26): 27549 - 27559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. An, Y. Sun, M. Fisher, and M. B. Rettig Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-{kappa}B dependent Mol. Cancer Ther., June 1, 2004; 3(6): 727 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mabuchi, M. Ohmichi, Y. Nishio, T. Hayasaka, A. Kimura, T. Ohta, M. Saito, J. Kawagoe, K. Takahashi, N. Yada-Hashimoto, et al. Inhibition of NF{kappa}B Increases the Efficacy of Cisplatin in in Vitro and in Vivo Ovarian Cancer Models J. Biol. Chem., May 28, 2004; 279(22): 23477 - 23485. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Guo, U. N. Verma, R. B. Gaynor, E. P. Frenkel, and C. R. Becerra Enhanced Chemosensitivity to Irinotecan by RNA Interference-Mediated Down-Regulation of the Nuclear Factor-{kappa}B p65 Subunit Clin. Cancer Res., May 15, 2004; 10(10): 3333 - 3341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Cortes, D. Thomas, C. Koller, F. Giles, E. Estey, S. Faderl, G. Garcia-Manero, D. McConkey, G. Patel, R. Guerciolini, et al. Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias Clin. Cancer Res., May 15, 2004; 10(10): 3371 - 3376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bonvini, H. D. Rosa, N. Vignes, and A. Rosolen Ubiquitination and Proteasomal Degradation of Nucleophosmin-Anaplastic Lymphoma Kinase Induced by 17-Allylamino-Demethoxygeldanamycin: Role of the Co-Chaperone Carboxyl Heat Shock Protein 70-Interacting Protein Cancer Res., May 1, 2004; 64(9): 3256 - 3264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. G. Mimnaugh, W. Xu, M. Vos, X. Yuan, J. S. Isaacs, K. S. Bisht, D. Gius, and L. Neckers Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity Mol. Cancer Ther., May 1, 2004; 3(5): 551 - 566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Kamat, T. Karashima, D. W. Davis, L. Lashinger, M. Bar-Eli, R. Millikan, Y. Shen, C. P. N. Dinney, and D. J. McConkey The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo Mol. Cancer Ther., March 1, 2004; 3(3): 279 - 290. [Abstract] [Full Text]
|
|
|
|
|
|
H.-F. Zhang, A. Tomida, R. Koshimizu, Y. Ogiso, S. Lei, and T. Tsuruo Cullin 3 Promotes Proteasomal Degradation of the Topoisomerase I-DNA Covalent Complex Cancer Res., February 1, 2004; 64(3): 1114 - 1121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. T. Nawrocki, B. Sweeney-Gotsch, R. Takamori, and D. J. McConkey The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts Mol. Cancer Ther., January 1, 2004; 3(1): 59 - 70. [Abstract] [Full Text]
|
|
|
|
|
|
P. M. Voorhees, E. C. Dees, B. O'Neil, and R. Z. Orlowski The Proteasome as a Target for Cancer Therapy Clin. Cancer Res., December 15, 2003; 9(17): 6316 - 6325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Tergaonkar, V. Bottero, M. Ikawa, Q. Li, and I. M. Verma I{kappa}B Kinase-Independent I{kappa}B{alpha} Degradation Pathway: Functional NF-{kappa}B Activity and Implications for Cancer Therapy Mol. Cell. Biol., November 15, 2003; 23(22): 8070 - 8083. [Abstract] [Full Text] [PDF]
|
|
|
|
